drugset / Trial / NCT00890305

Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone

NCT00890305

Phase 2 Completed 171 enrolled Medivation, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial will be performed in previously untreated patients with metastatic colorectal cancer. The study will evaluate the safety, tolerability and efficacy of the study drug, CT-011, in combination with FOLFOX chemotherapy (FOLFOX4 or mFOLFOX6) compared with treatment by FOLFOX alone.

Timeline

Start
2009-05
Primary completion
2012-05
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Leucovorin Small molecule 200 mg/m2
Subject Leucovorin Small molecule 400 mg/m2
Subject Oxaliplatin Small molecule 85 mg/m2
Subject Pidilizumab Monoclonal antibody 3 mg/kg Intravenous
Subject fluorouracil Small molecule 400 mg/m2
Subject fluorouracil Small molecule 600 mg/m2
Subject fluorouracil Small molecule 1200 mg/m2

Indications